Abstract

AimEven though TIVADs have been implanted for a long time, immediate complications are still occurring. The aim of this work was to review different techniques of placing TIVAD implants to evaluate the aetiology of immediate complications.MethodsA systematic literature review was performed using the PubMed, Cochrane and Google Scholar databases in accordance with the PRISMA guidelines. The patient numbers, number of implanted devices, specialists involved, implant techniques, implant sites and immediate complication onsets were studied.ResultsOf the 1256 manuscripts reviewed, 36 were eligible for inclusion in the study, for a total of 17,388 patients with equivalent TIVAD implantation. A total of 2745 patients (15.8%) were treated with a surgical technique and 14,643 patients (84.2%) were treated with a percutaneous technique. Of the 2745 devices (15.8%) implanted by a surgical technique, 1721 devices (62.7%) were placed in the cephalic vein (CFV). Of the 14,643 implants (84.2%) placed with a percutaneous technique, 5784 devices (39.5%) were placed in the internal jugular vein (IJV), and 5321 devices (36.3%) were placed in the subclavian vein (SCV). The number of immediate complications in patients undergoing surgical techniques was 32 (1.2%) HMMs. In patients treated with a percutaneous technique, the number of total complications were 333 (2.8%): 71 PNX (0.5%), 2 HMT (0.01%), 175 accidental artery punctures AAP (1.2%) and 85 HMM (0.6%). No mortality was reported with either technique.ConclusionThe percutaneous approach is currently the most commonly used technique to implant a TIVAD, but despite specialist’s best efforts, immediate complications are still occurring. Surgical cut-down, 40 years after the first implant, is still the only technique that can avoid all of the immediate complications that can be fatal.

Highlights

  • In 1980, Dr John Niederhuber realized an idea when faced with a family situation. His wife, who was affected by cancer, needed multiple venous infusions that progressively damaged the status of her veins. This inspired the invention of the totally implantable venous access device that was first manufactured by Pharmacia® [1]

  • We limited this study to the last 10 years because in our previous study [8], we evaluated the immediate complications associated with the surgical cut-down and percutaneous approach technique between the first implant and 2010

  • A total of 17,496 patients received the equivalent number of Totally implantable venous access device (TIVAD) implants, and they were analysed

Read more

Summary

Introduction

In 1980, Dr John Niederhuber realized an idea when faced with a family situation. His wife, who was affected by cancer, needed multiple venous infusions that progressively damaged the status of her veins. This inspired the invention of the totally implantable venous access device that was first manufactured by Pharmacia® [1]. The Seldinger technique has been used for Langenbeck’s Archives of Surgery (2021) 406:1739–1749 years [2], but Dr Niederhuber chose a surgical technique using a small peripheral vein to place his catheter in the vena cava [3]. No percutaneous technique was utilized for the first 10 years, and no immediate lethal complications have been reported

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call